

Dr Matthew Jenner's publications

2013

- Bird, J.M., Owen, R.G., D'Sa, S., Snowden, J.A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F.E., Morgan, G.J., Cavenagh, J., Low, E., Behrens, J., **Jenner, M.W.** on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology. Guidelines for the diagnosis and management of myeloma 2013. Online publication: [http://www.bcsHQguidelines.com/documents/MYELOMA_GUIDELINE_updated_29_aug_RG_jzw_\(3\).pdf](http://www.bcsHQguidelines.com/documents/MYELOMA_GUIDELINE_updated_29_aug_RG_jzw_(3).pdf)
- Publicover, A., Richardson, D. S., Davies, A., Hill, K. S., Hurlock, C., Hutchins, D., **Jenner, M. W.**, Johnson, P. W., Lamb, J., Launders, H., McKeag, N., Newman, J. and Orchard, K. H. (2013), Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. *Br J Haematol*, 162: 107–111.

2010

- **Jenner, M.W.** & Morgan, G.J.. Plasma cell neoplasms. In: Magrath, I, editor. *The Lymphoid Neoplasms*. London: Hodder Arnold. 2010.
- Schey, S.A., Morgan, G.J., Ramasamy, K., Hazel, B., Ladon, D., Corderoy, S., **Jenner, M.**, Phekoo, K., Boyd, K. & Davies, F.E. (2010) The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. *Br J Haematol*, 150, 326-333.
- Walker, B.A., Leone, P.E., Chiecchio, L., Dickens, N.J., **Jenner, M.W.**, Boyd, K.D., et al (2010) A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. *Blood*, 116, e56-65.

2007

- Davies, F.E., Wu, P., **Jenner, M.**, Srikanth, M., Saso, R. & Morgan, G.J. (2007) The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. *Haematologica*, 92, 1149-1150.
- **Jenner, M.W.**, Leone, P.E., Walker, B.A., Ross, F.M., Johnson, D.C., Gonzalez, D., et al (2007) Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. *Blood*, 110, 3291-3300.
- Morgan, G.J., Schey, S.A., Wu, P., Srikanth, M., Phekoo, K.J., **Jenner, M.** & Davies, F.E. (2007) Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. *Br J Haematol*, 137, 268-269.

2006

- Morgan, G.J., Krishnan, B., **Jenner, M.** & Davies, F.E. (2006) Advances in oral therapy for multiple myeloma. *Lancet Oncol*, 7, 316-325.